Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03992456
Title Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Panitumumab

Regorafenib

Trifluridine-tipiracil hydrochloride

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST